课题基金 / 基金详情

Elucidating the Genomic Determinants of Outcomes in Idiopathic Pulmonary Fibrosis

Elucidating the Genomic Determinants of Outcomes in Idiopathic Pulmonary Fibrosis
阐明特发性肺纤维化结果的基因组决定因素
批准号:
10670456
负责人:
Justin M Oldham
金额:
$10.35万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-01 至 2023-02-28

项目摘要

项目成果

Justin M Oldham的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a rare, but devastating interstitial lung disease characterized by a progressive decline in lung function and a median survival of 3-5 years after diagnosis. Despite the poor prognosis, IPF follows a highly variable clinical course, whereby most patients experience gradual disease progression, some demonstrate relative stability and a small group dies from rapidly progressive disease. Anti- fibrotic therapies were recently approved for the treatment of IPF, but it remains unclear which IPF phenotypes derive the most benefit. Recent advances in genomic technology provide an excellent opportunity to improve our understanding of IPF progression and treatment response. In this proposal, I aim to take advantage of these genomic advances to identify single nucleotide polymorphisms (SNPs) linked to relevant IPF outcomes. I will do this using DNA samples collected from patients enrolled in past and current IPF clinical trials, along with two large IPF registries. My central hypothesis is that patients genetically predisposed to death, disease progression and treatment response can be prospectively identified using SNPs linked to these endpoints. I will first conduct a genome-wide survival analysis to identify SNPs linked to early IPF mortality. I will then genotype relevant susceptibility and outcome-associated SNPs in several clinical trial datasets to determine whether they predict relevant trial endpoints, including pulmonary function decline and hospitalization. Finally, I will genotype SNPs at potential pharmacogenetic loci to determine whether such SNPs modulate the response to anti-fibrotic therapy. This work will advance my long-term career goal of incorporating genetics into clinical decision-making in patients with IPF. Concurrently I will pursue a career development plan that will provide outstanding mentorship, hands-on laboratory experience and additional training in genetic epidemiology, statistical genetics, and bioinformatics. This K23 award is vital to successful completion of this proposal and timely execution of my career development plan, as it will provide the time necessary to meet the realistic milestones that have set in conjunction with my advisory committee. Ultimately this award will allow me to successfully compete for R01 funding aimed at advancing my long-term goal above.
期刊论文(22)
专著(0)
科研奖励(0)
会议论文
Association study of human leukocyte antigen (HLA) variants and idiopathic pulmonary fibrosis.
人类白细胞抗原(HLA)变异与特发性肺纤维化的关联研究。
DOI: 10.1101/2023.07.20.23292940
发表时间: 2023
期刊: the preprint server for health sciences
影响因子: --
作者: [Guillen-Guio B]
通讯作者: Guillen-Guio B
Weighing on Our Minds: Baseline BMI and Weight Loss as Predictors of Interstitial Lung Disease Outcome.
掂量我们的心:基线 BMI 和体重减轻作为间质性肺疾病结果的预测因子。
DOI: 10.1016/j.chest.2021.11.013
发表时间: 2022
期刊: Chest
影响因子: 9.6
作者: [Pugashetti,JanelleVu, Oldham,JustinM]
通讯作者: Oldham,JustinM
Rebuttal From Drs Oldham and Danoff.
奥尔德姆博士和丹诺夫博士的反驳。
DOI: 10.1016/j.chest.2018.08.1071
发表时间: 2019
期刊: Chest
影响因子: 9.6
作者: [Oldham,JustinM, Danoff,SonyeK]
通讯作者: Danoff,SonyeK
Clinical Genetics in Interstitial Lung Disease.
间质性肺病的临床遗传学。
DOI: 10.3389/fmed.2018.00116
发表时间: 2018
期刊: Frontiers in medicine
影响因子: 3.9
作者: [Newton,ChadA, Molyneaux,PhilipL, Oldham,JustinM]
通讯作者: Oldham,JustinM
16
    Proteomic Profiling of Idiopathic Pulmonary Fibrosis Progression Trajectory
    Interrogation of the inflammasome to identify biomarkers of progressive interstitial lung disease
    Interrogation of the inflammasome to identify biomarkers of progressive interstitial lung disease
    海外基金